Cancer Vaccine Market Research Report 2025
Cancer Vaccine Market Global Industry Analysis and Forecast (2025-2032) by Types (preventative and therapeutic), Route of Administration (Intramuscular, Intravenous), Technology (Molecular-based, Vector-based, and Cell-based, Recombinant Cancer Vaccines), Application (Cervical Cancer, Bladder Cancer, Prostate Cancer, Lung Cancer, and Others), End users (Hospitals, Government & Organization Supply, and Others), Regional Insights
Cancer Vaccine Market Synopsis:
Cancer Vaccine Market Size Was Valued at USD 8.7 Billion in 2024, and is Projected to Reach USD 17.68 Billion by 2032, Growing at a CAGR of 9.3% from 2025-2032.
A cancer vaccine is a type of immunotherapy designed to stimulate the body's immune system to recognize and attack cancer cells, either to prevent cancer or to treat existing cancer. Unlike vaccines that prevent viral or bacterial infections, cancer vaccines target the patient's own cells that have become cancerous. Cancer vaccine applications represent a growing and innovative area in oncology, aiming to prevent, treat, or reduce the recurrence of cancer through immunological intervention. There are two types of cancer vaccines (Preventive and Therapeutic Vaccine). In preventive care, cancer vaccines are used to protect individuals from virus-related cancers by immunizing them against cancer-causing pathogens. In therapeutic settings, cancer vaccines are used to treat existing cancer by stimulating the immune system to recognize and destroy cancer cells. According to the World Health Organization, cancer is the second leading cause of death worldwide, with 10 million deaths and 20 million new cases. It is estimated that the number will rise by 60% in the next two decades, and by 2040, the number of cancer patients will rise up to 30 million.
Cancer vaccines are driven by the rising number of cancer cases worldwide, which increases the need for better and safer treatments. They are also driven by the rising number of cancer cases worldwide, which increases the need for better and safer treatments. Thus, the market studied is expected to grow due to the abovementioned factors.
Top Active Players Involved Are:
“Astellas Pharma (Japan), Bilthoven Biologicals (Netherlands), Blokhin National Medical Research Center of Oncology (Russia), Bristol-Myers Squibb (Spain), Cure & Sure Biotech (China) ,Eli Lilly (US), Elicio Therapeutics (Europe) ,Enara Bio (UK), GSK (Mexico), Herzen Moscow Oncology Research Institute (Russia), Immunovaccine Inc. (Canada), IQVIA (Bulgaria) ,Merck (US), Nouscom (Europe), Novartis (US) ,Otsuka Pharmaceutical (Japan), Oxford Vacmedix (OVM), (UK) Sanofi Canada (Canada), Scancell (UK) ,Serum Institute of India (SII) (India) ,Transgene (France) ,Ultimovacs (Europe), Vaxon Biotech (France), ViciniVax (Netherlands), Xiamen Innovax Biotech Co., Ltd. (China), Other Active Players”.
Cancer Vaccine Market Growth:
Growth drivers Rising Cancer Prevalence and Increased Awareness
- The global cancer burden continues to increase, creating a larger need for effective treatment and prevention strategies, including cancer vaccines.
- Public awareness about the importance of vaccination and preventive healthcare is growing, leading to increased adoption of cancer vaccines.
- Simultaneously, awareness of the need for vaccination and preventive care is also on the rise, and this has helped to improve acceptance and acceptance of cancer vaccines in different parts of the world. The increasing number of people with cancer globally has enormously heightened demands for proper treatment and prevention, and cancer vaccines have offered hope as a solution.
- However, recent progress in immunotherapy and biotechnology has been increasing the effectiveness of these vaccines, which are increasingly becoming an option in cancer control and prevention. The rising health threat has secured global attention in novel strategies for cancer control.
Restraints High Development And Manufacturing Costs
- High research and development costs are a significant obstacle to the expansion of the cancer vaccines segment. The process of development is extremely sophisticated, with long research and development cycles, strict regulatory standards, and sophisticated manufacturing technologies. The regulatory environment may also differ by region, causing inconsistencies in regulation and making the development, approval, and commercialization process more difficult.
- Additionally, all these challenges together lead to higher time and cost pressures, which can cause delays in access to novel cancer vaccine solutions. High production and research costs remain a major obstacle to the growth of the cancer vaccines market High production and development expenses hinder the growth rate in the cancer vaccines segment. The vaccine development process is complicated, given the long R&D time, strict regulation, and sophisticated production technologies.
- Thus, this uncertainty may result in differences in regulatory supervision among various authorities, making the manufacturing development and approval procedures more difficult.
Expansion Opportunities New Prospects in the Worldwide Market for Cancer Vaccines
- Personalized cancer vaccines are becoming more and more popular, especially ones that use mRNA technology. These vaccinations are more effective and have fewer side effects because they are customized to the tumour characteristics of specific patients.
- Personalized vaccines are becoming an innovation factor in future cancer therapy regimens due to the impact of advances in biotechnology and increasing interest in targeted therapies. Manufacturing personalized vaccines for specific tumor-associated antigens promises to better treat patients while reducing side effects.
- However, this treatment also promises a significant milestone in the history of precision oncology, which holds new promise for patients with challenging to treat cancer vaccine production of personalized vaccines, aimed at specific tumor-associated antigens, hold great promise for increased efficacy and reduced side effects.
Challenges Funding and Investment and Regulatory Hurdles
- Developing new vaccines requires substantial financial investment and long-term commitment from governments and private organizations. Increased funding is essential for advancing research and development and clinical trials require to approve the cancer vaccines.
- Obtaining vaccine approval through regulatory channels is sometimes a complicated and time-consuming task, involving great care in assuring safety while working to achieve efficiency. Additionally, simplifying these processes without sacrificing safety standards is necessary to speed up the availability of life-saving vaccines and make them available in the market. However, navigating regulatory pathways for vaccine approval can be complex and time-consuming. Streamlining these processes without compromising safety is crucial for advancing vaccine availability.
Cancer Vaccine Market Segment Analysis:
Cancer Vaccine Market is segmented based on Type, Application, and Region
By Type, Recombinant Cancer Vaccine Segment is Expected to Dominate the Market During the Forecast Period
- Recombinant cancer vaccines are anticipated to account for a major portion of the Cancer immunotherapy market through the forecast period due to increased demand for efficient and novel cancer vaccines and increasing technological developments. Global market volumes overall were around 7 billion doses in 2023.
- Recombinant vaccines are produced through the use of yeast or bacteria in order to produce a single viral or bacterial protein by large-scale production. Infectious diseases such as Oncovirus like HPV, HBV account for 12% of newly diagnosed cancers. As per the Frontiers article, in January 2022, therapeutic HSV-1 vaccination intravenously administered with additionally, VC2-OVA increased mouse strength and activated a powerful preventive antitumor response, resulting in beneficial outcomes
- Thus, these create the immune response of the immune system quite comparable to that of native infectious microorganisms. The DNA of the microorganism binds to the vector and activates the human immune system. The other recombinant vaccine is the DNA vaccine, or genetic vaccine. The naked DNA plasmid is delivered intramuscularly or via the "Gene Gun" delivery system. Therefore, the expansion of the market sector is projected to be aided by the growing research and development efforts demonstrating the effectiveness of recombinant cancer vaccines.
By Application, Lung Cancer Segment Held the Largest Share in 2024
- The lung cancer application is expected to retain its leading position. This is due to the rising occurrence of lung cancer, mainly as a result of increased smoking and popularity of unhealthy products like e-cigarettes. Being the most common cause of cancer deaths worldwide, lung cancer needs immunotherapy treatments to control the advanced levels of the disease. In accordance with the WHO, lung cancer is the world's leading cause of death.
- Leading uses of immune checkpoint inhibitors in therapy are fueling segment growth. Besides, the market players are increasingly engaged in the development and introduction of new immune checkpoint inhibitors for the treatment of lung cancer patients. According to Merck.com, in January 2023, Merck & Co., Inc. was approved to use KEYTRUDA (pembrolizumab) as an additional treatment option for patients after platinum-based chemotherapy and surgical resection. The medication is approved in patients with stage IB, II, IIIA non-small cell lung cancer. Thus, increasing occurrence and mortality caused by lung cancer are the major factors driving the segment growth.
Cancer Vaccine Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast Period
- The Cancer vaccines market in North America is most likely to witness a remarkable growth as a result of the high incidence of cancer in this region, coupled with the highly developed health infrastructure in the region. The United States also possesses a very highly developed healthcare infrastructure compared to many other advanced nations in the world.
- Additionally, the high incidence of cancer in the region is also most likely to generate an enormous demand for effective Cancer vaccines, thus contributing significantly to fueling the overall growth of the market. According to, the American Cancer Society's 2022 report states that in excess of 1.9 million new instances of cancer are likely to be diagnosed in the United States alone during the year 2022. Due to the high incidence of cancer and due to the geriatric population consisting of a massive majority suffering acutely, a corresponding related higher demand for the effective therapeutics exists in the nation.
- The increased demand for cancer vaccines is expected to enhance the growth of the industry in the United States. Even though the initial area of interest for the revolutionary technology lies in Triple Negative Breast Cancer, there is most likely scope for it to be effective in curing other forms of breast cancer too in the times to come. Thus, the above factors are likely to enhance the market growth over the forecast period in the region.
Cancer Vaccine Market Key Active Players:
- Astellas Pharma (Japan)
- Bilthoven Biologicals (Netherlands)
- Blokhin National Medical Research Center of Oncology (Russia)
- Bristol-Myers Squibb (Spain)
- Cure & Sure Biotech (China)
- Eli Lilly (US)
- Elicio Therapeutics (Europe)
- Enara Bio (UK)
- GSK (Mexico)
- Herzen Moscow Oncology Research Institute (Russia)
- Immunovaccine Inc. (Canada)
- IQVIA (Bulgaria)
- Merck (US)
- Nouscom (Europe)
- Novartis (US)
- Otsuka Pharmaceutical (Japan)
- Oxford Vacmedix (OVM) (UK)
- Sanofi Canada (Canada)
- Scancell (UK)
- Serum Institute of India (SII) (India)
- Transgene (France)
- Ultimovacs (Europe)
- Vaxon Biotech (France)
- ViciniVax (Netherlands)
- Xiamen Innovax Biotech Co., Ltd. (China)
- Other Active Players
Key Industry Developments in the Cancer Vaccine Market:
- In September 2024: Novartis has made notable advancements in cancer vaccine development, particularly focusing on mRNA-based therapies. The company holds approximately 150 patents in mRNA cancer therapeutics, emphasizing innovations in adjuvants and scalable production techniques.
- In January 2024: GSK and Oxford establish the GSK-Oxford Cancer ImmunoPrevention Programme to advance novel cancer research. Collaboration unites GSK and Oxford’s complementary expertise in the science of the immune system, vaccines and cancer biology.
|
CANCER VACCINE MARKET |
|||
|
Base Year: |
2024 |
Forecast Period: |
2025-2032 |
|
Historical Data: |
2018 to 2024 |
Market Size in 2024: |
USD 8.7 Bn |
|
Forecast Period 2025-32 CAGR: |
9.3 % |
Market Size in 2032: |
USD 17.68 Bn. |
|
Segments Covered: |
By Type |
|
|
|
By Route Of Administration |
|
||
|
By Technology |
|
||
|
By Application |
|
||
|
By End Users |
|
||
|
By Region |
|
||
|
Growth Driver: |
|
||
|
Limiting Factor |
|
||
|
Expansion Opportunity |
|
||
|
Challenge Barrier |
|
||
|
Companies Covered in the Report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Industry Ecosystem
3.4 Industry Value Chain Mapping
3.5 Strategic PESTLE Overview
3.6 Porter's Five Forces Framework
3.7 Regulatory Framework
3.8 Pricing Trend Analysis
3.9 Intellectual Property Review
3.10 Technology Evolution
3.11 Import-Export Analysis
3.12 Consumer Behavior Analysis
3.13 Investment Pocket Analysis
3.14 Go-To Market Strategy
Chapter 4: Cancer Vaccines Market by Types (2018-2032)
4.1 Cancer Vaccines Market Snapshot and Growth Engine
4.2
Frequently Asked Questions
What is the market size of the Cancer Vaccine Market?
Cancer Vaccine Market Size Was Valued at USD 8.7 Billion in 2024, and is Projected to Reach USD 17.68 Billion by 2032, Growing at a CAGR of 9.3% from 2025-2032.
What defines the Cancer Vaccine Market?
A cancer vaccine is a type of immunotherapy designed to stimulate the body's immune system to recognize and attack cancer cells, either to prevent cancer or to treat existing cancer. Unlike vaccines that prevent viral or bacterial infections, cancer vaccines target the patient's own cells that have become cancerous.
How is the Cancer Vaccine Market segmented?
The Cancer Vaccine Market is segmented into Type, Nature, Application, and Region. By Type, the market is categorized into preventative and therapeutic). By Route Of Administration, the market is categorized into Intramuscular, Intravenous. By Application, the market is categorized into Cervical Cancer, Bladder Cancer, Prostate Cancer, Lung Cancer. By End users, Hospitals, Government & Organization Supply, By Technology, Molecular-based, Vector-based, and Cell-based, Recombinant Cancer Vaccines. By Region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Russia; Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; The Netherlands; Italy; ; Spain; Rest of Western Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC), Middle East & Africa (Türkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil; Argentina, etc.).
Who are the Key Players in the Cancer Vaccine Market?
Astellas Pharma (Japan), Bilthoven Biologicals (Netherlands), Blokhin National Medical Research Center of Oncology (Russia), Bristol-Myers Squibb (Spain), Cure & Sure Biotech (China) ,Eli Lilly (US), Elicio Therapeutics (Europe) ,Enara Bio (UK), GSK (Mexico), Herzen Moscow Oncology Research Institute (Russia), Immunovaccine Inc. (Canada), IQVIA (Bulgaria) ,Merck (US), Nouscom (Europe), Novartis (US) ,Otsuka Pharmaceutical (Japan), Oxford Vacmedix (OVM), (UK) Sanofi Canada (Canada), Scancell (UK) ,Serum Institute of India (SII) (India) ,Transgene (France) ,Ultimovacs (Europe), Vaxon Biotech (France), ViciniVax (Netherlands) ,Xiamen Innovax Biotech Co., Ltd. (China) ,Other Active Players.
What is the Forecast Period Covered in the Cancer Vaccine Market Research Report?
The projected forecast period for the Cancer Vaccine Market Research Report is 2025-2032.
